A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

The results from two Phase 1 trials bolster the case that the gut microbiome plays a role in response to the drugs.

Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.

Meet some of the people featured in the July/August 2020 issue of The Scientist.

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

There’s a new cell-based cancer immunotherapy on the block.

Injecting the seasonal flu vaccine directly into clumps of malignant cells recruits immune cells to confront the cancer.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.